Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A good read, especially for newbies
https://www.griproom.com/fun/10-signs-your-stock-is-being-manipulated
Has anyone else noticed that more often than not, when commons are up, preferreds are down and vice versa. Too much of a pattern to just be coincidence.
“This appears to be very old news. Have any successful test cases been reported?”
If by “very old” you mean two days ago?, then yes
8K from August 25, 2022
SAN DIEGO, Aug. 25, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today development of a novel immunotherapy for treatment of solid tumors. Current cellular approaches to kill cancer involve administration of a specific type of modified T cell called "chimeric antigen receptor" (CAR) T cell. Despite significant progress being made in using CAR-T cells to treat leukemia, little progress has been made in solid tumors such as those found in lung, brain, breast, prostate and colon. It is believed that solid tumors possess an abnormal "microenvironment" which physically prevents T cells from entering the tumor, as well as inactivating T cells that do manage to enter. The microenvironment consists of surrounding blood vessels, immune cells, fibroblasts, signaling molecules and an extracellular matrix. The solid tumor is surrounded by its microenvironment and constantly interacts with it.
The current approach developed by the Company, for which a provisional patent application has been submitted, involves initial treatment of the tumor microenvironment with cells of the innate immune system called CAR-M and CAR-NK cells. These cells, which also begin to attack the tumor, are able to "normalize" the tumor microenvironment, thus allowing CAR-T cells to enter and attack the tumor.
"The company believes that taking this two-step approach – first softening up the target with CAR-M and CAR-NK cells and then bringing in the heavy artillery (CAR-T cells) will allow solid tumors to be successfully targeted by these cell therapies, thus greatly expanding the CAR-T market and ultimately saving people's lives," said Dr. David Koos, CEO and Chairman of the Company.
8K from August 9, 2022
Item 8.01 Other Events.
On August 9, 2022 KCL Therapeutics, Inc. ( a wholly owned subsidiary of Regen Biopharma, Inc. ) filed a provisional patent application with the United States Patent and Trademark Office covering methods, means and compositions of matter useful for treatment of cancer through enhancement of antitumor activity of chimeric antigen receptor (CAR) T cells through dedifferentiation of said cells. Chimeric antigen receptor (CAR)T cells are T cells that have been modified to attack specific antigens such as cancer cells. T cells are part of the immune system and develop from stem cells in the bone marrow.
You mean “steal”?
We’ll said
Quote: “So what do you think this means.
“ efficient actions to undertake in order to commercialize the Company’s NR2F6 intellectual property”
I guess it is all in how we interpret it!”
I agree. It’s how we interpret it. Biotech Research Group is a consulting firm. My interpretation was that they are assessing how RGBP should proceed to market with their product(s). It may certainly include a price evaluation, but does not specifically mention that.
Just my “interpretation”
Wrong, but your right to think so
Hey 29..., first let me say I am long here and have a stake in RGBP since 2015. Also, I’m a follower of your and, for the most part, admire your input and DD. But.... to quote the 8k of Oct 18th
On October 18, 2021 Regen Biopharma, Inc. (“Company”) has provided a Scope of Work order to Biotech Research Group directing Biotech Research Group to perform an independent assessment of work conducted to date on behalf of the Company by the Company’s Contract Research Organization in order to assist the Company in determining what would be the most efficient actions to undertake in order to commercialize the Company’s NR2F6 intellectual property as well as assist the Company with regulatory strategy with regard to the Company’s NR2F6 intellectual property . Total consideration to be paid by the Company to Biotech Research Group for providing these services is $25,000. The termination date of this Scope of Work Order is November 15, 2021.
I don’t read anything in this that mentions or even hints of a “price assessment”. I am hopeful, but this reminds me of the “buyout” pump of last month
All imho
Boards are sure quiet this morning. It 3 and 2 with bases loaded. Everyone on the edge of their seats waiting for that last pitch.
Does anyone know what happens with the stock trading when a buyout takes place? Is trading halted just before the announcement? Does trading continue after the announcement up to the point of the buyout? What happens to the available shares....if they are included, where does that money go? Not predicting, just curious. Glta
Look at the last 3 to 4 months and study the 8ks, 10k’s and 10q’s. Why would anyone take the time to work on these things to get the company current, revive the IPs and patents. Do all that is required to get the company current with the maximum IP and Patents in place. Final reports ARE coming. The ball will not be dropped at this point. Major company processes moving forward. What??? Who knows, but major plans in place. Don’t try to guess what’s going to happen. Buy the dips to increase your holdings/value. Don’t sell until you personally believe that the pps is where you want it for your personal financial situation. Some, that my be .10. Other that may be $1.00. Whatever it is. Do your own dd and set your price. There will be movement in the days ahead. Don’t be greedy. Set you exit strategy based on YOUR situation and trade accordingly. Gltya.
I reached out myself to TD due to mixed messages being reported here. I would think that if the rules changed, there would have been some sort of communication sent out to stock holders, just as there was when the restriction was first imposed.
Below is the response I just received from TD. (Notice the mention (“to align more with Charles Schwab”)
From: Message Center Client Services
To: pstartrader
Date: 5:51pm ET 8/11/2021
Hello Xxxxxx,
Thank you for contacting TD Ameritrade. My name is Victoria and I am happy to help!
We have extended the OTC securities date from August 13, 2021 to align more with Charles Schwab and the date they select for the restrictions to begin. The extended date is still TBD, but will be around the end of August/early September. The new amendments of SEC Rule 15c2-11 will still go in effect on September 28, 2021.
We greatly appreciate your business and know you have a choice where you invest. If there is anything else we can do for you, or could have done better, please let us know.
We look forward to serving your needs for years to come.
Respectfully,
Victoria Main
Trader Support, Trader Services
TD Ameritrade
800-672-2098
TD Ameritrade, Inc., member FINRA/SIPC. Not an offer or solicitation to conduct business in any jurisdiction where we are not authorized to do business. Communications may be subject to review.
Usually funds are available in 3 to 5 days. You should expect to be funded Thur or Fri
Maybe Tuesday Koosday? As he used to be known for years ago
Unfortunately, I’m all tapped out. But that means no more pressure. I can sit back and watch the ride. No worries about pull-backs. Just sitting back and waiting for the inevitable (filings, current, possible merger/buyout). Love being in this position. Ignoring most blah, blah, blah
Good morning ANT. Is Thursday Koos day?
Depository Trust Company
The DTC offers net settlement obligations at the end of each day from trading in equity, debt, and money market instruments. ... That means they deposit and hold securities at the DTC, which appear in the records of an issuer's stock as the sole registered owner of those securities deposited at the DTC.
Bx3’s calculations would be a life changer for anyone, but I knew what I had. Even at 437500, it’s a life changer for me
Well, I’m tapped out. 1.75 mil RGBP commons and 150k Preferred. Now it’s just a waiting game. The million dollar question is when to cash out?????? All depends on news and the quality/quantity of the news. If we knew where the high will be (with this stock or any other), then we would all be millionaires. Based on the data and the company info (8k’s), I will be happy with $.25 common and/or $1.00 preferred in the short term (next 6 months or so). Do your own DD, but good luck to you all. IMO
Well, I’m tapped out. 1.75 mil RGBP commons and 150k Preferred. Now it’s just a waiting game. The million dollar question is when to cash out?????? All depends on news and the quality/quantity of the news. If we knew where the high will be (with this stock or any other), then we would all be millionaires. Based on the data and the company info (8k’s), I will be happy with $.25 common and/or $1.00 preferred in the short term (next 6 months or so). Do your own DD, but good luck to you all. IMO
Joe, they’re not talking about them”preferred” specifically. They are comparing the two stocks from the same company. Based on your logic, that could not be done on either board. Let’s move on
Not exactly the news we were all anticipating (maybe next week), but news none the less......
Regen BioPharma, Inc. Files Utility Patent Application on Immune Based Therapy for Cancer
8:30 am ET September 16, 2015 (PR Newswire) PrintRegen BioPharma, Inc. (OTCBB: RGBP) and (PINK: RGBP) announced today the filing of a utility patent application with the United States Patent and Trademark Office covering a novel cancer immunotherapy which induces activation of dendritic cells inside the body in order to stimulate immune-based rejection of cancer. The application builds on Regen's existing expertise in the area of dendritic cells including publications together with scientific advisory board member Dr. Wei-Ping Min (1-3), Professor at the University of Western Ontario, as well as purchase of issued patent # 8,389,708.
"Our filed IND # 16200 for dCellVax leverages dendritic cells that are modified outside of the body to trigger an immune response against breast cancer. In the newly filed patent application we cover means of activating dendritic cells inside the body, with the hope of stimulating T cell responses to clear prostate cancer," said Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma. "Effectively treating cancer requires a multi-level attack; by leveraging ex vivo activated dendritic cells combined with means of activating dendritic cells in vivo, we anticipate synergistic tumor responses."
Dendritic cells are known as "professional antigen presenting cells", meaning that they activate T cells, which are the effectors of the immune system. By reprogramming the immune system to attack cancer, Regen BioPharma aims to provide a non-toxic and effective means of treating cancer, while sparing patients the side effects of chemotherapy and/or radiation therapy.
"Regen BioPharma is excited about accumulation of intellectual property in its immuno-oncology program. By protecting the inventions of our scientists we aim to not only bring new products to the market, but also to position ourselves for potential licensing and co-development transactions," said David Koos, President, CEO and Chairman of Regen BioPharma, Inc.
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
References
-- Zhang et al. J Transl Med. 2014 May 22;12:142.
-- Li et al. J Transl Med. 2012 Jan 31;10:19
-- Zheng et al. Int J Cancer. 2013 Feb 15;132(4):967-77.
Contact Information Regen BioPharma Inc. David R. Koos, PhD Chairman & Chief Executive Officer +1-619-702-1404 Phone +1-619-330-2328 Fax http://www.regenbiopharma.com david.koos@regenbiopharma.com
I am a long and agree with your post, except for the very last statement "all green on the horizon". That is true, assuming that the GLP lab produces the same results as RGBP's.
all IMO, RBGP
Ron, I'm with TD and my divi shares ARE showing up on the "positions and balances" page. No ticker yet, but under the #75886M201.
I agree CV, and thanks to you and Traz for the info
Safety study on Hema specifically
I've only been around (mostly in the shadows) since last June, but do any of you "long-timers" know how long it took BMSN/RGBP to do their own initial safety study?
How can they be announcing FDA approval at the conference, if the GLP lab for final FDA testing hasn't even been decided on yet. That is of course, if you are talking about Hema. All IMO.
Quote:
________________________________________________________________
He stated that once FINRA approves the price point, which he said he was not able to disclose to me because it is private, BMA Securities will have a 30 day exclusivity where no other market makers will be allowed to set the market for RGBP
_________________________________________________________________
What is the status BMAK's exclusivity for 30 days and how does it work?
[color=red]Just curious....
@ 12:06:15, two transactions (800,000 & 199,999) total 999,999
@ 12:06:35/48 two transactions (800,001 & 199,998) total 999,999
@ 12:08:17/18 two transactions (50,000 & 949,999) total 999,999
@ 12:10:34/37 two transactions (624,846 & 375,153) total 999,999
Am I missing something here or just trying to read too much in to this?????